Pradeep Nair, MD
Interventional Cardiology · Houma, LANPI 1659517670
Payments from drug & device makers
Across 503 payments — averaging $438.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$87K
- Surmodics, Inc.$55K
- Boston Scientific$22K
- Cardiovascular Systems Inc.$13K
- Angiodynamics, Inc.$9K
- Abbott$8K
- plus $26K from 44 others
Across 1 payment — averaging $4200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$4K
What the payments were for
- Consulting fees$137,61365%
- Speaking & faculty fees$32,07515%
- Travel & lodging$15,4707%
- Food & beverage$20,38210%
- Education$4320%
- Other$6,4003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$74,373
- Sublime 014 Rx PTA Balloon Dilatation Catheter$61,812
- Sublime Radial Access 018 RX PTA Dilatation Catheter$24,652
- Sublime Microcatheter, 014, 65cm, Straight$21,952
- Sublime Microcatheter, 014, 65cm, Angle$21,952
- Sublime Microcatheter, 018, 200cm, Straight$15,209
- Diamondback Peripheral$13,415
- Sublime Radial Access Guide Sheath$9,300
- Pounce Thrombectomy System$7,238
- Diamondback Coronary$7,200
- Sublime Microcatheter, 035, 200cm, Angle$6,600
- GENERAL VASCULAR INTERVENTION$6,451
- VenaCure 1470 Pro$6,400
- Ultreon$5,500
- (R11) US EQ Undivided$4,900
- GENERAL - THERAPIES$3,215
- Pounce Venous Thrombectomy System$3,209
- Ranger$2,400
- Penumbra Coil 400$2,392
- Indigo System$2,392
How this compares
$220,371 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $335,376 |
| VyndamaxTafamidis | 11 | $285,696 |
| XareltoRivaroxaban | 386 | $275,118 |
| Repatha SureclickEvolocumab | 125 | $90,320 |
| BrilintaTicagrelor | 110 | $69,615 |
| EntrestoSacubitril/Valsartan | 43 | $44,379 |
| JardianceEmpagliflozin | 19 | $21,699 |
| Praluent PenAlirocumab | 32 | $17,146 |
| FarxigaDapagliflozin Propanediol | 15 | $14,093 |
| ClopidogrelClopidogrel Bisulfate | 1,012 | $10,245 |
| VascepaIcosapent Ethyl | 16 | $8,158 |
| Atorvastatin Calcium | 761 | $6,469 |
| Metoprolol Succinate | 425 | $5,335 |
| Rosuvastatin Calcium | 396 | $5,112 |
| Ezetimibe | 254 | $4,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $88 | $621,072353 claims |
| Johnson & JohnsonXarelto | $863 | $275,118386 claims |
| AstraZenecaBrilinta, Farxiga | $125 | $83,708125 claims |
| NovartisEntresto | $34 | $44,37943 claims |
| Boehringer IngelheimJardiance | $14 | $21,69919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Houma
- Craig WalkerHouma$5.5M
- Richard AbbenHouma$483K
- Eric EngeronHouma$377K
- Matthew FinnHouma$80K
- Anil ChagarlamudiHouma$27K
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
- James JenkinsNew Orleans$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.